BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24080589)

  • 1. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
    Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
    Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Point mutations of genes encoding proteins involvedin RNA splicing in patients with myelodysplastic syndromes].
    Barańska M; Czerwińska-Rybak J; Gil L; Komarnicki M
    Pol Merkur Lekarski; 2015 Jan; 38(223):5-10. PubMed ID: 25763580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spliceosomal factor mutations and mis-splicing in MDS.
    Hershberger CE; Daniels NJ; Padgett RA
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF3B1 mutant myelodysplastic syndrome: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
    Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
    Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.
    Visconte V; Makishima H; Maciejewski JP; Tiu RV
    Leukemia; 2012 Dec; 26(12):2447-54. PubMed ID: 22678168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing factor mutations in myelodysplasia.
    Ogawa S
    Int J Hematol; 2012 Oct; 96(4):438-42. PubMed ID: 23054646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
    Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
    Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
    [No Abstract]   [Full Text] [Related]  

  • 18. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
    Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
    Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
    Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
    Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.